Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month Low – Here’s What Happened

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares hit a new 52-week low during trading on Wednesday. The company traded as low as $40.38 and last traded at $40.44, with a volume of 595,855 shares changing hands. The stock had previously closed at $42.01.

Analyst Ratings Changes

Several equities analysts have commented on SUPN shares. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, September 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $62.40.

Supernus Pharmaceuticals Stock Performance

The stock has a market capitalization of $2.30 billion, a P/E ratio of -20.61, a price-to-earnings-growth ratio of 0.74 and a beta of 0.55. The company has a 50-day moving average price of $43.95 and a two-hundred day moving average price of $46.46.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million during the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company’s revenue for the quarter was up 32.4% on a year-over-year basis. During the same period last year, the firm posted $0.40 earnings per share. Research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several large investors have recently bought and sold shares of SUPN. BlackRock Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $434,871,000. Bank of America Corp DE bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $28,887,000. Assenagon Asset Management S.A. bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at about $27,428,000. Rice Hall James & Associates LLC purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $22,800,000. Finally, Bank of New York Mellon Corp purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $17,553,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.